In August 2012, a clinical trial launched for an inhibitor targeting metastatic hormone-sensitive breast cancer. Early results showed strong efficacy, and now this treatment is accessible to everyone who qualifies.
Afinitor, containing the active ingredient everolimus, enables patients to postpone chemotherapy by an average of 11 months.
Clinical Trial Insights
Forty hospitals joined the August trial. Initial findings match international studies, with patients experiencing reduced pain and tumor-related symptoms shortly after starting. Afinitor is well-tolerated, with few side effects.
Health Insurance Coverage
Insurers have approved reimbursement, prompting early trial conclusion. Afinitor treatment is now widely available.
